"340B is going away." People have said that for 30 years. VytlOne's CEO explains why they keep being wrong.
Kim Tzoumakas came to pharmacy after two decades as a healthcare lawyer. Her core argument: 340B isn't a loophole or a relic. It's infrastructure. Here's how that belief shapes the way she builds product, runs a CFO conversation, and draws the line on AI.